Brief: Intensity Therapeutics Receives Orphan Drug Designation For The Three Key Ingredients In Int230-6 For The Treatment Of Soft Tissue Sarcoma
07/09/2023 15:09
Intensity Therapeutics Inc INTS.O :
* INTENSITY THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION
FOR THE
THREE KEY INGREDIENTS IN INT230-6 FOR THE TREATMENT OF SOFT
TISSUE SARCOMA
Source text for Eikon: ID:nPn85rFW1a
Further company coverage: INTS.O
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing